Dishman plans Asia's largest cancer drug unit...

Ahmedabad-based Dishman Pharmaceutical & Chemicals Ltd is planning to invest Rs 500 crores for its two upcoming SEZs.

The company has completed acquisition of land for its pharmaceutical and chemical SEZ spread in about 390 acres near Bavla. Besides, the company is on verge of completing land acquisition for its Engineering SEZ as well. Dishman will apply for notification of both the SEZ in next 15 to 30 days, the company today informed BSE.

The company expects to begin work on both the SEZ by last quarter of calander year 2008. Dishman is in the process of setting up Asia's largest facility to manufacture cancer drugs and other high potency drugs at its Bavla facility.

This facility is designed and being commissioned by its subsidiary Carbogen Amics AG (CA), who has expertise in this area. The company has shelled out around Rs 50 crores for the construction work of this facility.

Besides, Dishman is heading towards manufacturing and marketing of disinfectant and sanitization products in India, Saudi Arabia and Australia.

The company will make formulated products for hospitals, domestic use and industrial disinfection. In India and Australia, this will be done by company and its Australian subsidiary, respectively.

In Saudi, this will be done by a joint venture called Dishman Arabia Ltd. with a Saudi partner. The company targeting to reach Rs 100 crore sales in 3 years from this new division.

Source: Business Standard